#United States #Atlanta #gene therapy #UT Southwestern #Kleefstra Syndrome

New Partnership to Tackle Kleefstra Syndrome

In a significant step forward for patients with Kleefstra syndrome, IDefine, the Kleefstra Syndrome Foundation, has announced a research collaboration with UT Southwestern Medical Center. This partnership aims to develop a gene therapy focused on replacing the EHMT1 gene, which is crucial for brain development and function, but is compromised in individuals affected by this rare neurodevelopmental disorder.

Kleefstra syndrome, characterized by a range of symptoms including intellectual disabilities, speech impediments, low muscle tone, seizures, and various behavioral issues, presents a profound challenge for affected individuals and their families. Unfortunately, there are currently no approved treatments available for this condition. The collaboration aims to bring hope and a pathway to potential therapies that could change lives.

The research program will be led by Dr. Steven Gray, a renowned professor at UT Southwestern and director of the UTSW Gene Therapy Program. Over the next two years, Dr. Gray and his team will explore the feasibility and safety of employing next-generation gene delivery technologies tailored to target the central nervous system (CNS). This innovative approach also prioritizes the safe regulation of gene expression, ensuring that the treatment is as effective and safe as possible.

Eric Scheeff, PhD, the chief scientific officer of IDefine, expressed optimism regarding this collaboration, stating, "This landmark research partnership represents a meaningful step forward in our mission to accelerate research that can lead to a first treatment for Kleefstra syndrome. We are especially honored to collaborate with Dr. Steven Gray and the esteemed UT Southwestern Gene Therapy Program. Their expertise allows us to envision a future where effective treatments are possible."

The partnership is aimed at advancing a leading-edge gene replacement approach, stepping away from conventional treatments and moving toward innovative solutions that harness the power of gene therapy. By replacing the dysfunctional EHMT1 gene, researchers hope to alleviate the severe symptoms associated with this syndrome, thereby improving the quality of life for patients.

Dr. Gray highlighted the potential of gene therapy: "Advances in gene therapy and CNS-targeted delivery technologies are creating new opportunities to develop potential treatments for complex neurodevelopmental disorders like Kleefstra syndrome. Our goal is not only to test the efficacy of the EHMT1 gene replacement but also to conduct this research while emphasizing safety and regulatory standards. We are thankful for the partnership with IDefine, which supports this crucial research endeavor."

IDefine has committed to providing around $310,000 in funding for this pre-clinical research, with the program set to continue until April 2028. This funding marks a critical investment in the potential to transform the lives of families struggling with the effects of Kleefstra syndrome.

Founded in 2020 by parents of children diagnosed with Kleefstra syndrome, IDefine is a nonprofit organization dedicated to supporting individuals and families impacted by this condition. Their mission is to accelerate the research needed to develop promising treatments and a potential cure, ensuring that nobody faces the challenges of Kleefstra syndrome alone. The organization is committed to driving scientific research, forming collaborative partnerships with medical professionals and researchers, and fostering a supportive community.

For those interested in following the advancements made in this field, IDefine encourages engagement and awareness. More information can be found on their official website at IDefine.org.

This collaboration not only signifies hope for those diagnosed with Kleefstra syndrome but also exemplifies the potential of partnerships between advocacy organizations and medical institutions in the pursuit of life-changing medical breakthroughs.